Company news

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) news

Every Monte Rosa Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) news

Press releases & updates

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular ...

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patie...

Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential...

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide ...

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretr...

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Su...

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metasta...

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular...

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue De...

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Trea...

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatmen...

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential...

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from...

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Mole...

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue ...

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecul...

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheu...

Monte Rosa Therapeutics Announces Leadership Team Promotions

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflam...

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader...

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024